Primary sclerosing cholangitis is a chronic cholestatic liver disease that is characterised by an obliterative inflammatory fibrosis of the biliary tract. This chronic inflammation frequently results in bile duct obliteration, biliary cirrhosis, hepatic failure, and sometimes in cholangiocarcinoma.
Although the first description of primary sclerosing cholangitis was made a century ago by Hoffman' in 1867, over the next 100 years the disease remained a medical rarity. The advent of endoscopic cholangiography in the 1970s, however, enabled the diagnosis to be made in an ever increasing number of patients. This led to the publication in 1980 of two reviews of large numbers of patients with primary sclerosing cholangitis from the Mayo Clinic2 and the Royal Free Hospital.3 These studies described the clinical, histological, and radiological features of the characteristic chronic cholestatic syndrome of primary sclerosing cholangitis. Interest With the advent of liver transplantation, it has become important to identify prognostic factors to predict the risk of progression to liver failure and death. These factors would be useful in deriving survival models which can be used to identify individual primary sclerosing cholangitis patients at low, moderate, and high risk. A number of these models have already been constructed for primary biliary cirrhosis. Unfortunately, studies from different units have provided conflicting results. The Yale study was the first to use multivariate analysis.' This showed that hepatomegaly and a serum bilirubin concentration >25 mmol/l were the only independent discriminators ofa poor prognosis.40 In contrast, the Mayo Clinic, also using multivariate analysis, found that age, serum bilirubin concentration, blood haemoglobin concentration, presence or absence of inflammatory bowel disease, and histological stage on liver biopsy were independent predictors of high risk of dying.42 To add to the confusion, the Royal Free group identified serum bilirubin, age, and the site of biliary involvement as indicators of a poor prognosis, whereas disease localised to the intrahepatic ducts was associated with a favourable outcome.4' The message from these variable results is that larger multicentre studies are needed.
The natural history of asymptomatic patients with primary sclerosing cholangitis is less clearcut. The diagnosis is made incidentally when a persistently raised alkaline phosphate activity is discovered, usually in a patient with ulcerative colitis. There has been controversy as to the relative number of asymptomatic patients who will progress and the rate of progression to symptomatic chronic liver disease. The Yale group described 11 asymptomatic primary sclerosing cholangitis patients observed for a mean follow up period of three years43: none of this small group developed symptoms. In addition, Aadland et How can these studies be equated? The Mayo Clinic and Royal Free Hospital are tertiary referral centres and, inevitably, new asymptomatic patients will be referred at a later stage in their disease process. Our own unpublished observations show that about one third of 35 asymptomatic patients have developed symptoms and two patients have died over a median follow up of five years. On balance, it seems that most asymptomatic patients will progress but that there may well be a subset who do not progress clinically over many years.
As yet there are no risk factors that have been identified to predict which asymptomatic patients will go on to develop liver failure or cholangiocarcinoma. In the light of potential therapeutic intervention further studies are needed in this important area.
Conclusion
The last decade has seen major advances in our understanding in all aspects of primary sclerosing cholangitis. It is to be hoped that the next 10 years will be equally productive and indicate the infectious or toxic agent which triggers the immune mediated biliary destruction in genetically susceptible subjects. Undoubtedly, accurate survival models will be developed from multicentre data which will allow optimal timing of medical therapy and liver transplantation. In addition, further studies will be needed to predict which patients are at risk of developing cholangiocarcinoma.
